A randomized phase 2 study investigating 3 dosing regimens of radium-223 dichloride (Ra-223) in bone metastatic castration-resistant prostate cancer (mCRPC).

被引：6
|
作者：
Sternberg, Cora N.
Saad, Fred
Graff, Julie Nicole
Peer, Avivit
Vaishampayan, Ulka N.
Leung, Eugene
Rosenbaum, Eli
Gurney, Howard
Epstein, Richard
Davis, Ian D.
Wu, Bingyan
Trandafir, Lucia
Wagner, Volker Jean
Hussain, Maha
机构：
[1] San Camillo Forlanini Hosp, Rome, Italy
[2] Ctr Hosp Univ Montreal, Montreal, PQ, Canada
[3] Oregon Hlth & Sci Univ, Portland, OR USA
[4] Rambam Hlth Care Ctr, Haifa, Israel
[5] Karmanos Canc Ctr, Detroit, MI USA
[6] Ottawa Hosp, Ottawa, ON, Canada
[7] Davidoff Ctr, Rabin Med Ctr, Petah Tiqwa, Israel
[8] Westmead Hosp, Westmead, NSW, Australia
[9] St Vincents Hosp, Kinghorn Canc Ctr, Sydney, NSW, Australia
[10] Monash Univ, Eastern Hlth Clin Sch, Melbourne, Australia
[11] Bayer HealthCare Pharmaceut Inc, Whippany, NJ USA
[12] Bayer Consumer Care AG, Basel, Switzerland
[13] Northwestern Univ Feinber, Robert H Lurie Canc Ctr, Div Hematol Oncol, Chicago, IL USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 15期
关键词：
D O I：
10.1200/JCO.2018.36.15_suppl.5008
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5008
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase IIa study of radium-223 dichloride (Ra-223) alone or in combination with abiraterone acetate or enzalutamide in metastatic castration-resistant prostate cancer (mCRPC)
    Petrylak, D. P.
    Vaishampayan, U. N.
    Patel, K. R.
    Higano, C. S.
    Albany, C.
    Dawson, N. A.
    Mehlhaff, B. A.
    Quinn, D. I.
    Nordquist, L. T.
    Wagner, V. J.
    Shen, J.
    Trandafir, L.
    Sartor, O.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 340 - 341
  • [2] Fracture risk after radium-223 (Ra-223) in metastatic castration resistant prostate cancer (mCRPC).
    Alonzi, Roberto
    Parker, Chris C.
    Tunariu, Nina
    Koh, Dow-Mu
    Staffurth, John
    Blackledge, Matthew D.
    Padhani, Anwar R.
    Tree, Alison
    Stidwill, Helen
    Finch, Jessica
    Chatfield, Peter
    Perry, Sophie
    Tovey, Holly
    Hall, Emma
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [3] Pain efficacy with radium-223 (Ra-223) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) in the PARABO observational study
    Palmedo, H.
    Ahmadzadehfar, H.
    Eschmann, S.
    Selkinski, I.
    Straube, F.
    Niesen, A.
    Schoenberger, J.
    Barsegian, V.
    Liepe, K.
    Mottaghy, F. M.
    Guan, R.
    Pinkert, J.
    Buetikofer, S.
    Herrmann, K.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S641 - S641
  • [4] Pain analyses from the phase 3 randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases
    Schrader, A. J.
    Nilsson, S.
    Sartor, O.
    Bruland, O.
    Fang, F.
    Aksnes, A-K
    Parker, C.
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 59 - 59
  • [5] Pain analyses from the phase 3 randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases
    Schrader, A. J.
    Nilsson, S.
    Sartor, O.
    Bruland, O.
    Fang, F.
    Aksnes, A. K.
    Parker, C.
    [J]. ONKOLOGIE, 2013, 36 : 17 - 18
  • [6] Phase 3 study of radium-223 dichloride (Ra-223) in Asian patients (pts) with castration-resistant prostate cancer (CRPC) and symptomatic bone metastases (mets)
    Sun, Y.
    Shi, H.
    Chen, C. -H.
    Lee, J. L.
    Kang, T. W.
    Park, S. H.
    Wu, T. L.
    Ng, Q. S.
    Keam, B.
    Wong, S. C. A.
    Tay, M. H.
    Ding, Q.
    Li, F.
    Ng, D. C. E.
    Liu, X.
    Zhang, Z.
    Guo, J.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 73 - 74
  • [7] Pain efficacy with radium-223 (Ra-223) in the REASSURE global, prospective, observational study of men with metastatic castration-resistant prostate cancer (mCRPC)
    Higano, C. S.
    Dizdarevic, S.
    Sundar, S.
    Agarwal, N.
    Essler, M.
    Song, D.
    George, S.
    Shore, N. D.
    Kurtinecz, M.
    Verholen, F.
    Sandstrom, P.
    Sartor, O.
    George, D. J.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S640 - S641
  • [8] Pain evaluation in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra-223) in the PARABO observation study
    Palmedo, H.
    Eschmann, S.
    Werner, A.
    Selinski, I.
    Moellers, M-O.
    Kalinovsky, J.
    Benson, A.
    Poeppel, T.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 336 - 336
  • [9] Fracture risk in men with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 (Ra 223)
    Hijab, A.
    Tunariu, N.
    Tovey, H.
    Alonzi, R.
    Tree, A.
    Staffurth, J.
    Blackledge, M.
    Padhani, A. R.
    Stidwill, H.
    Finch, J.
    Chatfield, P.
    Perry, S.
    Koh, D-M.
    Hall, E.
    Parker, C.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S539 - S539
  • [10] Efficacy of radium-223 dichloride in castration-resistant metastatic prostate cancer
    Sobrevilla Calvo, Pedro de Jesus
    [J]. GACETA MEXICANA DE ONCOLOGIA, 2016, 15 : 26 - 27
12345